Dissemin is shutting down on January 1st, 2025

Published in

Society of Nuclear Medicine, Journal of Nuclear Medicine, 8(58), p. 1249-1254, 2017

DOI: 10.2967/jnumed.116.184218

Links

Tools

Export citation

Search in Google Scholar

Prognostic Value of Bone Marrow Tracer Uptake Pattern in Baseline PET Scans in Hodgkin Lymphoma: Results from an International Collaborative Study

This paper was not found in any repository, but could be made available legally by the author.
This paper was not found in any repository, but could be made available legally by the author.

Full text: Unavailable

Green circle
Preprint: archiving allowed
  • If required by funding agency
Green circle
Postprint: archiving allowed
Red circle
Published version: archiving forbidden
Data provided by SHERPA/RoMEO

Abstract

RATIONALE: Positron Emission Tomography/Computed Tomography (PET/CT)-ascertained bone marrow involvement (BMI) constitutes the single most important reason for upstaging by PET/CT in Hodgkin lymphoma (HL). However, BMI assessment in PET/CT can be challenging. This study analysed the clinico-pathological correlations and prognostic meaning of different patterns of bone marrow (BM)-Fluorodeoxyglucose (FDG)-uptake in HL. PATIENTS AND METHODS: 180 newly diagnosed early unfavourable and advanced stage HL patients, all scanned at baseline and after 2 Adriamycin-Bleomycin-Vinblastine-Dacarbazine (ABVD) courses with FDG-PET, enrolled in two International studies aimed at assessing the role of interim PET scan in HL, were retrospectively included. Patients were treated with ABVD x 4-6 cycles and involved-field radiation when needed, and no treatment adaptation on interim PET scan was allowed. Two blinded reviewers independently reported the scans. RESULTS: Thirty-eight patients (21.1%) had focal lesions (fPET+), 10 of them with a single (unifocal) and 28 with multiple (multifocal) BM lesions. Fifty-three (29.4%) had pure strong (> liver) diffuse uptake (dPET+) and 89 (48.4%) showed no or faint (≤ liver) BM uptake (nPET+). BM biopsy (BMB) was positive in 6/38 (15.7%) of fPET+, in 1/53 (1.9%) of dPET+ and in 5/89 (5.6%) of nPET+. dPET+ was correlated with younger age, higher frequency of bulky disease, lower hemoglobin levels, higher leucocyte counts and similar diffuse uptake in the spleen. Patients with pure dPET+ had an identical 3-year Progression Free Survival (3Y-PFS) to patients without any FDG uptake (82.9% and 82.2%, respectively P = 0.918). However patients with fPET+ (either unifocal or multifocal) had a 3-Y-PFS significantly inferior to patients with dPET+ and nPET+ (66.7% and 82.5%, respectively, P = 0.03). The kappa-values for inter-observer agreement were 0.84 for focal uptake and 0.78 for diffuse uptake. CONCLUSION: We confirmed that FDG-PET scan is a reliable tool for BMI assessment in HL and BMB is no longer needed for routine staging. Moreover, the inter-observer agreement for BMI in this study proved excellent and only focal FDG BM uptake should be considered as a harbinger of HL.